In emerging countries and in countries where a large part of the population survives on a low income, the cost of assistance or treatment is often unaffordable.
Spread the word. Help a child. Even the highest level of commitment and dedication is no use if nobody knows
So, for the association's work to be successful, it is crucial to bring it to the attention of as many people as possible. Donating Your donations help to support the work of our foundation
Every donation, however large or small, helps us in our fight against this disorder or directly benefits those people affected by thalassemia.
Our work focuses on supporting those affected by thalassemia and their relatives, promoting structural prevention and raising public awareness of this genetic disorder.
An estimated 4.6 million children and young people suffer from thalassemia worldwide (including Germany), a figure that demonstrates a clear social, cultural and political need for sustained and wide-ranging forms of assistance.
Here, you can find out more about the disorder of thalassemia, get an insight into our work and our concerns and discover how you can help in easy and practical terms.
Donation information from the Executive Board
In the spirit of the transparency requested by both sides on the subject of donors and donations, we inform interested parties, friends and supporters that bluebird bio (Switzerland) GmbH has supported our work for the years 2020 to 2022 with a donation. The amount is EUR 5,400. This is EUR 1,800 per year.
The donated money may only be used for the statutory purposes of the association. Our statutes are published on this website.
Thalassämiehilfe ohne Grenzen e. V. (thalassemia help without borders) thanks for the experienced appreciation
bluebird bio Inc. tells about itself: ″We are developing therapies that have the potential to transform the lives of people with severe genetic and rare diseases and cancer. Our current platform is just the beginning. We are committed to continuing to develop gene therapy technologies and capabilities that have broad potential beyond the core indications.″
More information: https://www.bluebirdbio.com/about-us
Juergen M. Beith, Chairman - January 2020